Catalysts / FDMT
Upcoming FDA decisions and readouts we track for 4D Molecular Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for 4D Molecular Therapeutics (FDMT, listed on Nasdaq). They cover 2 programmes: 4D-710 (Cystic fibrosis lung disease) and 4D-150 (Wet age-related macular degeneration).
First on the list: the Phase 1/2 readout for 4D-710 (Cystic fibrosis lung disease), guided by the company to Q4 2026. The furthest-out event tracked is H2 2027. By stage, the upcoming rows are 1 Phase 1/2 readout and 2 Phase 3 readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics FDMT · Nasdaq | 4D-710 | Cystic fibrosis lung disease | Q4 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| 4D Molecular Therapeutics FDMT · Nasdaq | 4D-150 | Wet age-related macular degeneration | Q2 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| 4D Molecular Therapeutics FDMT · Nasdaq | 4D-150 | Wet age-related macular degeneration | H2 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList